A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-02

Study Completion Date

2023-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to treatment arms based on results of AML mutation testing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

NCT04038437

Acute Myeloid Leukemia

COMPLETED PHASE1

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

NCT04195945

Acute Myeloid Leukemia Myeloid Neoplasm

ACTIVE_NOT_RECRUITING PHASE2

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

NCT03335267

Leukemia, Myeloid, Acute

COMPLETED PHASE2

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

NCT04269213

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia With Myelodysplasia-Related Changes Secondary Acute Myeloid Leukemia +1 more

ACTIVE_NOT_RECRUITING PHASE2

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

NCT03844997

Acute Myeloid Leukemia AML

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Group Type EXPERIMENTAL

CPX-351

Intervention Type DRUG

Up to 2 induction and 2 consolidation courses will be offered

Venetoclax

Intervention Type DRUG

Will be administered over specified duration during induction and consolidation courses

Arm B

Group Type EXPERIMENTAL

CPX-351

Intervention Type DRUG

Up to 2 induction and 2 consolidation courses will be offered

Midostaurin

Intervention Type DRUG

Will be administered over specified duration during induction and consolidation courses

Arm C

Group Type EXPERIMENTAL

CPX-351

Intervention Type DRUG

Up to 2 induction and 2 consolidation courses will be offered

Enasidenib

Intervention Type DRUG

Will be administered over specified duration during induction and consolidation courses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPX-351

Up to 2 induction and 2 consolidation courses will be offered

Intervention Type DRUG

Venetoclax

Will be administered over specified duration during induction and consolidation courses

Intervention Type DRUG

Midostaurin

Will be administered over specified duration during induction and consolidation courses

Intervention Type DRUG

Enasidenib

Will be administered over specified duration during induction and consolidation courses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vyxeos JZP351 Venclexta Rydapt Idhifa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 to ≤ 75 years at the time of informed consent.
* Newly diagnosed AML according to World Health Organization (WHO) pathological criteria (with at least 20% blasts in the peripheral blood or bone marrow).
* ECOG performance status of 0 to 2.
* Laboratory values fulfilling the following:

* Serum creatinine \< 2.0 mg/dL.
* Serum total bilirubin \< 2.0 mg/dL. (For subjects with Gilbert's Syndrome and serum total bilirubin ≥ 2.0 mg/dL, the medical monitor should be contacted.)
* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 times the upper limit of normal (ULN). (Note: If elevated liver enzymes \> ULN are related to disease, contact medical monitor to discuss.)
* Cardiac ejection fraction ≥ 50% by echocardiography or multiple gated acquisition scan (MUGA).
* Subjects with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period \> 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Subjects maintained on long-term nonchemotherapy treatment (eg, hormonal therapy) are eligible.

Exclusion Criteria

* Acute promyelocytic leukemia \[t(15;17)\].
* Subject has favorable risk cytogenetics ((t8;21), inv(16), t(16;16), or t15;17) karyotype abnormalities) as categorized by the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2014 for AML (NCCN 2014).
* Clinical evidence of active central nervous system (CNS) leukemia.
* Subjects with active (uncontrolled, metastatic) second malignancies.
* Subjects who have received prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood cell counts. (For example, a subject with myelodysplastic syndrome \[MDS\] who changes hypomethylating agent \[HMA\] dose and schedule after the diagnosis of AML is excluded. AML-type therapy, such as cytarabine alone \[\> 1g/m2/day\] or cytarabine plus an anthracycline as well as prior HSCT are also excluded.) All-trans-retinoic acid (ATRA) used empirically is permitted.
* Subjects receiving administration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to the first dose of study drug. In the event of rapidly proliferative disease, use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to Grade 1 or less prior to start of treatment.
* Subjects with myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging).
* Subjects with active or uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥ 72 hours.
* Current evidence of invasive fungal infection (blood or tissue culture). Subjects with recent fungal infection must have a subsequent negative culture to be eligible.
* Subjects with known human immunodeficiency virus (new testing not required) or evidence of active hepatitis B or C infection.
* Subjects with known history of Wilson's disease or other known copper-metabolism disorder.
* Subjects with other comorbidity that the investigator judges to be incompatible with conventional ICT, and / or the targeted agent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No